Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

BACKGROUND: Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis (MS). Mainly because of the risk of progressive multifocal leukoencephalopathy (PML), a substantial proportion of John Cunningham (JC) virus–positive patients switch to fingolimod. Previous reports show a cle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler
Main Authors: Leurs, Cyra E, van Kempen, Zoé LE, Dekker, Iris, Balk, Lisanne J, Wattjes, Mike P, Rispens, Theo, Uitdehaag, Bernard MJ, Killestein, Joep
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2017
Assuntos:
Original Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174622/
https://ncbi.nlm.nih.gov/pubmed/28823223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517726381
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados